Investigator

Aradhana M. Venkatesan

The University of Texas MD Anderson Cancer Center, Dept. of Abdominal Imaging, Division of Diagnostic Imaging

About

AMVAradhana M. Venka…
Papers(5)
Fertility Preservatio…Gynecologic Manifesta…Abdominopelvic compli…Human Papilloma Virus…RadioGraphics Update:…
Collaborators(10)
Ashish P. WasnikAtul B. ShinagareCarrie L. LangstraatDavid SwansonDavid T. FuentesDiego OdettoEkta MaheshwariErica LynnEvis SalaGiacomo Avesani
Institutions(8)
The University Of Tex…University of Michiga…Brigham And Womens Ho…Mayo ClinicHospital Italiano Bue…University Of Pittsbu…University Of Cambrid…Agostino Gemelli Univ…

Papers

Abdominopelvic complications of gynecologic malignancy: Essentials for radiologists

Gynecologic cancers are among the leading causes of cancer-related deaths among female patients, with over 80 % of patients experiencing persistent or long-term effects even after curative treatment. Abdominopelvic complications can arise from the disease itself or treatment-related factors. Tumor-related complications include effects from locoregional invasion (malignant bowel obstruction, obstructive uropathy), tumor rupture (and associated hemorrhage), hypercoagulability (leading to deep vein thrombosis), and infections (including tumor fistulization to the bowel or lower urinary tract, abscesses, pyometra, and/or superinfected necrosis). Treatment-related complications can be subdivided into those following surgery, radiotherapy, or systemic therapy, including immunotherapy. Postoperative complications include paralytic ileus, obstructions, fistulas, anastomotic leaks or strictures, vaginal cuff dehiscence, wound infections, lymphocele, and lymphedema. Radiotherapy-related toxicities include acute toxicities of diarrhea, cystitis, and vaginal mucositis, as well as chronic toxic effects, including radiation enteritis, bladder dysfunction, fistulas, pelvic insufficiency fractures, and sexual dysfunction. Complications of cytotoxic chemotherapy and targeted agents include myelosuppression, neuropathy, mucositis, neutropenic enterocolitis, pneumatosis intestinalis, bowel perforation, tumor-to-bowel fistula, pancreatitis, nephrotoxicity, osteoporosis, and bone loss. Immunotherapy-related toxicities include colitis, enteritis, hepatitis, and pancreatitis. The role of the radiologist in the detection and characterization of these complications is paramount, as imaging is integral to timely diagnosis and multidisciplinary management. An awareness of the spectrum of abdominopelvic complications affecting gynecologic oncology patients is essential to maximal diagnostic accuracy and optimal patient care.

Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Patients with Cervical Cancer Undergoing Definitive Chemoradiation

Abstract Purpose: Human papillomavirus (HPV) is a significant cause of cervical cancer. We hypothesized that detecting viral cell-free HPV DNA (cfDNA) before, during, and after chemoradiation (chemoRT) could provide insights into disease extent, clinical staging, and treatment response. Experimental Design: A total of 66 patients with locally advanced cervical cancer were enrolled between 2017 and 2023, with 49 receiving standard-of-care treatment and 17 participating in a clinical trial combining a therapeutic HPV vaccine (PDS0101; IMMUNOCERV). Plasma was collected at baseline, weeks 1, 3, and 5 of chemoRT, and 3 to 4 months after chemoRT. HPV cfDNA was quantified using droplet digital PCR targeting the HPV E6/E7 oncogenes of 13 high-risk types. MRI was performed at baseline and before brachytherapy. Results: The median follow-up was 23 months, with recurrence-free survival (RFS) of 78.4% at 2 years. Baseline nodal disease extent correlated with HPV cfDNA levels. HPV cfDNA levels peaked in week 1 of radiation and decreased through treatment. Patients receiving the PDS0101 vaccine had a higher rate of undetectable HPV type 16 cfDNA compared with those who received standard-of-care therapy. HPV cfDNA clearance correlated with better 2-year RFS (92.9% vs. 30%, log-rank; P = 0.0067). The strongest predictor of RFS was HPV cfDNA clearance in follow-up achieving a concordance index score of 0.83, which improved when combined with MRI response (concordance index, 0.88). Conclusions: HPV cfDNA levels change dynamically during chemoRT. HPV cfDNA levels at follow-up predict RFS, and delivery of therapeutic HPV vaccine with chemoRT was linked to rapid HPV cfDNA decline. Monitoring HPV cfDNA during and after chemoRT may guide tailoring of personalized treatment.

150Works
5Papers
32Collaborators
Genital Neoplasms, FemaleEndometrial NeoplasmsNeoplasm StagingDiagnosis, DifferentialNeoplasmsNeoplastic Syndromes, Hereditary

Positions

2014–

Researcher

The University of Texas MD Anderson Cancer Center · Dept. of Abdominal Imaging, Division of Diagnostic Imaging

2007–

Researcher

NIH Clinical Center · Dept. of Radiology and Imaging Sciences

Education

2001

Harvard Medical School

1995

Swarthmore College